SCHEMBL21695058

SCHEMBL21695058

CCOCCOCCOCCOC(=O)N1CCN(C(C)C)CC1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.42
POLB P06746 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
HTT P42858 1/20 0.42
CASP6 P55212 1/20 0.42
TSHR P16473 3/20 0.42
RECQL P46063 1/20 0.41
CHRM2 P08172 1/20 0.40
CHRM1 P11229 1/20 0.40
KDM4E B2RXH2 1/20 0.40
GAA P10253 1/20 0.39
LMNA P02545 1/20 0.39
FAAH O00519 1/20 0.38
MGLL Q99685 1/20 0.38
ABL1 P00519 1/20 0.38
MAPT P10636 1/20 0.38
RIN1 Q13671 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
HRH3 Q9Y5N1 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25588991 0.88 ALDH1A1 (0.37) ALDH1A1POLBSMN1; SMN2HTTCASP6
SCHEMBL21695057 0.88 HRH3 (0.40) ALDH1A1POLBSMN1; SMN2HTTCASP6
SCHEMBL20436763 0.88 ALDH1A1 (0.37) ALDH1A1POLBSMN1; SMN2HTTCASP6
SCHEMBL19661326 0.86 CASP6 (0.36) ALDH1A1POLBSMN1; SMN2HTTCASP6
SCHEMBL681679 0.85 ALDH1A1 (0.56) ALDH1A1POLBSMN1; SMN2HTTCASP6
SCHEMBL21694972 0.82 ALDH1A1 (0.34) ALDH1A1POLBSMN1; SMN2HTTCASP6
SCHEMBL19661318 0.82 ALDH1A1 (0.34) ALDH1A1POLBSMN1; SMN2HTTCASP6
SCHEMBL25589656 0.80 HRH3 (0.41) ALDH1A1POLBSMN1; SMN2HTTCASP6
SCHEMBL22115802 0.78 ALDH1A1 (0.48) ALDH1A1POLBSMN1; SMN2HTTTSHR
SCHEMBL13503648 0.75 KIT (0.44) ALDH1A1POLBSMN1; SMN2HTTCASP6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11384105-B2 Processes for preparing oligomers SAREPTA THERAPEUTICS, INC. (US) 2022-07-12 US disclosed
US-20210198296-A1 PROCESSES FOR PREPARING OLIGOMERS SAREPTA THERAPEUTICS, INC. (US) 2021-07-01 US disclosed
US-10875880-B2 Processes for preparing oligomers SAREPTA THERAPEUTICS, INC. (US) 2020-12-29 US disclosed
US-20200040020-A1 PROCESSES FOR PREPARING OLIGOMERS JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT 2020-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200040020-A1 PROCESSES FOR PREPARING OLIGOMERS NOP2, PCBP1, RNGTT ALDH1A1 4511/4885POLB 96/4885SMN1; SMN2 401/4885
US-20210198296-A1 PROCESSES FOR PREPARING OLIGOMERS PCBP1, RNGTT, PHAX ALDH1A1 4252/4885POLB 43/4885SMN1; SMN2 696/4885
US-10875880-B2 Processes for preparing oligomers NOP2, PCBP1, RNGTT ALDH1A1 4511/4885POLB 96/4885SMN1; SMN2 401/4885
US-11384105-B2 Processes for preparing oligomers NOP2, RNGTT, PCBP1 ALDH1A1 4482/4885POLB 143/4885SMN1; SMN2 471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.